)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Xintela
Xintela (XINT) investor relations material
Xintela Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary28 Aug, 2026
Executive summary
Net sales increased to SEK 1,317 thousand in Q2 2026, up from SEK 872 thousand year-over-year, driven by the EQGen project.
Loss before tax improved to SEK -9,762 thousand from SEK -12,119 thousand year-over-year due to higher sales and lower costs.
XSTEM achieved its primary safety objective in a clinical study for difficult-to-heal venous leg ulcers.
Positive results from the knee osteoarthritis study with XSTEM were published, supporting disease-modifying effects.
SEK 30 million convertible loan secured from principal shareholder to accelerate XSTEM development and repay previous debt.
Financial highlights
Net sales for Q2 2026: SEK 1,317 thousand (Q2 2025: SEK 872 thousand).
Loss before tax for Q2 2026: SEK -9,762 thousand (Q2 2025: SEK -12,119 thousand).
Loss per share for Q2 2026: SEK -0.01 (Q2 2025: SEK -0.02).
Cash and cash equivalents at June 30, 2026: SEK 30,724 thousand (June 30, 2025: SEK 10,532 thousand).
Operating loss for Q2 2026: SEK -9,683 thousand (Q2 2025: SEK -11,526 thousand).
Outlook and guidance
Focus on accelerating XSTEM's path to market through business development and partnerships.
Strategy includes early commercialization in select markets and ongoing efforts to secure further funding.
Continued development of XSTEM for wound indications is planned primarily through strategic partnerships.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Xintela
- XSTEM met key clinical milestones and secured new patents, supporting future commercialization.XINT
Q1 2026 - XSTEM clinical results drive partnership interest as financial losses widen but funding is secured.XINTQ4 2025
- XSTEM delivered long-term efficacy in osteoarthritis, with ongoing clinical and partnership progress.XINTQ3 2025
- XSTEM's highest dose halted cartilage loss and improved bone structure in OA patients for two years.XINTInvesting in Life Science 2025
- XSTEM osteoarthritis study completed; strong warrant uptake boosts cash amid ongoing losses.XINTQ2 2025
- Improved results, clinical progress, and new financing position Xintela for next-stage growth.XINTQ3 2024
- Losses narrowed as Xintela advanced clinical programs and secured new development agreements.XINTQ2 2024
- XSTEM's 18-month osteoarthritis results and EQSTEM's global licensing drive Xintela's Q1 progress.XINTQ1 2025
- Xintela reached key clinical milestones and strengthened its finances while pursuing new partnerships.XINTQ4 2024
Next Xintela earnings date
Q3 202627 Nov, 2026
Xintela
Next Xintela earnings date
Q3 202627 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Xintela AB is a Sweden-based biomedical company specializing in regenerative medicine and cancer treatments. The company focuses on developing therapies for cartilage damage and osteoarthritis using its proprietary XINMARK technology, which identifies specific stem cells that can develop into cartilage cells. In oncology, Xintela is working on targeted treatments for aggressive cancers, including glioblastoma. Through its subsidiary Targinta, the company also develops antibody-based therapies targeting cancer cells. The company is headquartered in Lund, Sweden, and its shares are listed on the Nasdaq Stockholm.